Wall Street Trims Ratings for Novo Nordisk Stock, as Ozempic’s Competition Grows

view original post

Guggenheim’s Seamus Fernandez cut his rating on Novo Nordisk stock to Hold from Buy on Thursday, as did Evan David Seigerman at BMO Capital Markets. The Danish drug company’s